{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:10:40Z","timestamp":1792714240826,"version":"4.5.0"},"reference-count":114,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Immunology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.smim.2026.102016","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T01:27:36Z","timestamp":1770773256000},"page":"102016","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Therapeutic immune tolerance for central nervous system autoimmune diseases \u2013 Prospects, challenges and pitfalls"],"prefix":"10.1016","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1301-2863","authenticated-orcid":false,"given":"Andreas","family":"Lutterotti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.smim.2026.102016_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.coi.2022.102266","article-title":"The increasing prevalence of autoimmunity and autoimmune diseases: an urgent call to action for improved understanding, diagnosis, treatment, and prevention","volume":"80","author":"Miller","year":"2023","journal-title":"Curr. Opin. Immunol."},{"issue":"3","key":"10.1016\/j.smim.2026.102016_bib2","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/s41582-023-00776-4","article-title":"Origins and immunopathogenesis of autoimmune central nervous system disorders","volume":"19","author":"Ramanathan","year":"2023","journal-title":"Nat. Rev. Neurol."},{"issue":"1","key":"10.1016\/j.smim.2026.102016_bib3","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00415-023-11910-z","article-title":"Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: attack therapy and long-term management","volume":"271","author":"Kumpfel","year":"2024","journal-title":"J. Neurol."},{"issue":"2","key":"10.1016\/j.smim.2026.102016_bib4","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1177\/1352458517751049","article-title":"ECTRIMS\/EAN Guideline on the pharmacological treatment of people with multiple sclerosis","volume":"24","author":"Montalban","year":"2018","journal-title":"Mult. Scler."},{"issue":"17","key":"10.1016\/j.smim.2026.102016_bib5","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1212\/WNL.0000000000005347","article-title":"Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology","volume":"90","author":"Rae-Grant","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.smim.2026.102016_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.640935","article-title":"Antigen-specific immune tolerance in multiple sclerosis-promising approaches and how to bring them to patients","volume":"12","author":"Lutterotti","year":"2021","journal-title":"Front Immunol."},{"key":"10.1016\/j.smim.2026.102016_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2025.101947","article-title":"The role of the adaptive immune system in the initiation and persistence of multiple sclerosis","volume":"78","author":"Afzali","year":"2025","journal-title":"Semin Immunol."},{"key":"10.1016\/j.smim.2026.102016_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2025.101944","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Insights into pathogenesis and biomarkers of prognosis","volume":"78","author":"Andersen","year":"2025","journal-title":"Semin Immunol."},{"key":"10.1016\/j.smim.2026.102016_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2025.101945","article-title":"The immunological processes behind aquaporin 4-antibody seropositive neuromyelitis optica spectrum disorders","volume":"78","author":"Bradl","year":"2025","journal-title":"Semin Immunol."},{"issue":"1","key":"10.1016\/j.smim.2026.102016_bib10","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1517\/13543784.2014.844788","article-title":"Antigen-specific tolerization approaches in multiple sclerosis","volume":"23","author":"Lutterotti","year":"2014","journal-title":"Expert Opin. Invest. Drugs"},{"key":"10.1016\/j.smim.2026.102016_bib11","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1146\/annurev.immunol.23.021704.115707","article-title":"Immunology of multiple sclerosis","volume":"23","author":"Sospedra","year":"2005","journal-title":"Annu Rev. Immunol."},{"issue":"2","key":"10.1016\/j.smim.2026.102016_bib12","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1055\/s-0036-1579739","article-title":"Immunology of multiple sclerosis","volume":"36","author":"Sospedra","year":"2016","journal-title":"Semin. Neurol."},{"issue":"1","key":"10.1016\/j.smim.2026.102016_bib13","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/WNO.0000000000001772","article-title":"The potential pathogenicity of myelin oligodendrocyte glycoprotein antibodies in the optic pathway","volume":"43","author":"Lerch","year":"2023","journal-title":"J. Neuroophthalmol."},{"issue":"9","key":"10.1016\/j.smim.2026.102016_bib14","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/S1474-4422(21)00218-0","article-title":"Myelin-oligodendrocyte glycoprotein antibody-associated disease","volume":"20","author":"Marignier","year":"2021","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.smim.2026.102016_bib15","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000060","article-title":"MOG antibody-associated diseases","volume":"2","author":"Reindl","year":"2015","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"4","key":"10.1016\/j.smim.2026.102016_bib16","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.smim.2026.102016_bib17","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/1742-2094-8-184","article-title":"Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders","volume":"8","author":"Mader","year":"2011","journal-title":"J. Neuroinflamm."},{"issue":"2","key":"10.1016\/j.smim.2026.102016_bib18","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.smim.2026.102016_bib19","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/WCO.0000000000001052","article-title":"Pathomechanisms in demyelination and astrocytopathy: autoantibodies to AQP4, MOG, GFAP, GRP78 and beyond","volume":"35","author":"Mader","year":"2022","journal-title":"Curr. Opin. Neurol."},{"issue":"12","key":"10.1016\/j.smim.2026.102016_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103465","article-title":"A comprehensive review of the advances in neuromyelitis optica spectrum disorder","volume":"22","author":"Siriratnam","year":"2023","journal-title":"Autoimmun. Rev."},{"issue":"10","key":"10.1016\/j.smim.2026.102016_bib21","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/s41582-024-01014-1","article-title":"NMOSD and MOGAD: an evolving disease spectrum","volume":"20","author":"Uzawa","year":"2024","journal-title":"Nat. Rev. Neurol."},{"issue":"9","key":"10.1016\/j.smim.2026.102016_bib22","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","article-title":"The spectrum of neuromyelitis optica","volume":"6","author":"Wingerchuk","year":"2007","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.smim.2026.102016_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0010455","article-title":"Patterns of antibody binding to aquaporin-4 isoforms in neuromyelitis optica","volume":"5","author":"Mader","year":"2010","journal-title":"PLoS One"},{"issue":"19","key":"10.1016\/j.smim.2026.102016_bib24","doi-asserted-by":"crossref","first-page":"12123","DOI":"10.1074\/jbc.M115.647149","article-title":"Mutagenesis of the aquaporin 4 extracellular domains defines restricted binding patterns of pathogenic neuromyelitis optica IgG","volume":"290","author":"Owens","year":"2015","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.smim.2026.102016_bib25","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1212\/WNL.0b013e318248dec1","article-title":"Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays","volume":"78","author":"Waters","year":"2012","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.smim.2026.102016_bib26","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: international MOGAD Panel proposed criteria","volume":"22","author":"Banwell","year":"2023","journal-title":"Lancet Neurol."},{"issue":"6","key":"10.1016\/j.smim.2026.102016_bib27","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/bpa.12084","article-title":"Aquaporin-4 antibodies (NMO-IgG) as a serological marker of neuromyelitis optica: a critical review of the literature","volume":"23","author":"Jarius","year":"2013","journal-title":"Brain Pathol."},{"issue":"8","key":"10.1016\/j.smim.2026.102016_bib28","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1080\/00207454.2022.2153046","article-title":"Neuromyelitis optica spectrum disorder: pathophysiological approach","volume":"134","author":"Mireles-Ramirez","year":"2024","journal-title":"Int J. Neurosci."},{"issue":"10","key":"10.1016\/j.smim.2026.102016_bib29","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/j.immuni.2024.08.005","article-title":"Autoantigen-specific CD4(+) T cells acquire an exhausted phenotype and persist in human antigen-specific autoimmune diseases","volume":"57","author":"Saggau","year":"2024","journal-title":"Immunity"},{"issue":"5","key":"10.1016\/j.smim.2026.102016_bib30","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000277","article-title":"Restoring immune tolerance in neuromyelitis optica: Part II","volume":"3","author":"Bar-Or","year":"2016","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"5","key":"10.1016\/j.smim.2026.102016_bib31","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200275","article-title":"MOG CNS autoimmunity and MOGAD","volume":"11","author":"Moseley","year":"2024","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"5","key":"10.1016\/j.smim.2026.102016_bib32","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000276","article-title":"Restoring immune tolerance in neuromyelitis optica: Part I","volume":"3","author":"Steinman","year":"2016","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"3-4","key":"10.1016\/j.smim.2026.102016_bib33","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jaut.2011.01.004","article-title":"Fine specificity of antibodies against AQP4: epitope mapping reveals intracellular epitopes","volume":"36","author":"Kampylafka","year":"2011","journal-title":"J. Autoimmun."},{"issue":"1","key":"10.1016\/j.smim.2026.102016_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0016083","article-title":"Functional characterization of aquaporin-4 specific T cells: towards a model for neuromyelitis optica","volume":"6","author":"Kalluri","year":"2011","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.smim.2026.102016_bib35","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s00401-015-1501-5","article-title":"Highly encephalitogenic aquaporin 4-specific T cells and NMO-IgG jointly orchestrate lesion location and tissue damage in the CNS","volume":"130","author":"Zeka","year":"2015","journal-title":"Acta Neuropathol."},{"issue":"8003","key":"10.1016\/j.smim.2026.102016_bib36","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/s41586-024-07079-8","article-title":"B cells orchestrate tolerance to the neuromyelitis optica autoantigen AQP4","volume":"627","author":"Afzali","year":"2024","journal-title":"Nature"},{"issue":"51","key":"10.1016\/j.smim.2026.102016_bib37","doi-asserted-by":"crossref","first-page":"14781","DOI":"10.1073\/pnas.1617859114","article-title":"Tolerance checkpoint bypass permits emergence of pathogenic T cells to neuromyelitis optica autoantigen aquaporin-4","volume":"113","author":"Sagan","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"3","key":"10.1016\/j.smim.2026.102016_bib38","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/eji.201646855","article-title":"Deletional tolerance prevents AQP4-directed autoimmunity in mice","volume":"47","author":"Vogel","year":"2017","journal-title":"Eur. J. Immunol."},{"issue":"5","key":"10.1016\/j.smim.2026.102016_bib39","article-title":"T cells targeting neuromyelitis optica autoantigen aquaporin-4 cause paralysis and visual system injury","volume":"3","author":"Cruz-Herranz","year":"2017","journal-title":"J. Nat. Sci."},{"issue":"1","key":"10.1016\/j.smim.2026.102016_bib40","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00401-011-0824-0","article-title":"Pathogenic T cell responses against aquaporin 4","volume":"122","author":"Pohl","year":"2011","journal-title":"Acta Neuropathol."},{"issue":"126","key":"10.1016\/j.smim.2026.102016_bib41","doi-asserted-by":"crossref","DOI":"10.3791\/56185","article-title":"Induction of paralysis and visual system injury in mice by T cells specific for neuromyelitis optica autoantigen aquaporin-4","author":"Sagan","year":"2017","journal-title":"J. Vis. Exp."},{"issue":"11","key":"10.1016\/j.smim.2026.102016_bib42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0015050","article-title":"Immunodominant T cell determinants of aquaporin-4, the autoantigen associated with neuromyelitis optica","volume":"5","author":"Nelson","year":"2010","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.smim.2026.102016_bib43","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/ana.24718","article-title":"Gut microbiome analysis in neuromyelitis optica reveals overabundance of Clostridium perfringens","volume":"80","author":"Cree","year":"2016","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.smim.2026.102016_bib44","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.msard.2015.12.004","article-title":"T-cell responses to distinct AQP4 peptides in patients with neuromyelitis optica (NMO)","volume":"6","author":"Vaknin-Dembinsky","year":"2016","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.smim.2026.102016_bib45","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/ana.23651","article-title":"Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter","volume":"72","author":"Varrin-Doyer","year":"2012","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.smim.2026.102016_bib46","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s13311-017-0594-z","article-title":"The gut microbiome in neuromyelitis optica","volume":"15","author":"Zamvil","year":"2018","journal-title":"Neurotherapeutics"},{"issue":"9","key":"10.1016\/j.smim.2026.102016_bib47","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/intimm\/dxr056","article-title":"Increased T-cell immunity against aquaporin-4 and proteolipid protein in neuromyelitis optica","volume":"23","author":"Matsuya","year":"2011","journal-title":"Int Immunol."},{"key":"10.1016\/j.smim.2026.102016_bib48","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jneuroim.2014.11.011","article-title":"Association of circulating follicular helper T cells with disease course of NMO spectrum disorders","volume":"278","author":"Li","year":"2015","journal-title":"J. Neuroimmunol."},{"issue":"3","key":"10.1016\/j.smim.2026.102016_bib49","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1080\/14728214.2020.1803828","article-title":"Emerging drugs for the treatment of neuromyelitis optica","volume":"25","author":"Duchow","year":"2020","journal-title":"Expert Opin. Emerg. Drugs"},{"issue":"6","key":"10.1016\/j.smim.2026.102016_bib50","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200494","article-title":"Long-term efficacy and safety of satralizumab in patients with neuromyelitis optica spectrum disorder from the SAkuraMoon open-label extension study","volume":"12","author":"Bennett","year":"2025","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.smim.2026.102016_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102538","article-title":"Review of approved NMO therapies based on mechanism of action, efficacy and long-term effects","volume":"46","author":"Brod","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"7","key":"10.1016\/j.smim.2026.102016_bib52","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing-remitting multiple sclerosis","volume":"358","author":"Hauser","year":"2008","journal-title":"N. Engl. J. Med"},{"issue":"1","key":"10.1016\/j.smim.2026.102016_bib53","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cell.2018.08.011","article-title":"Memory B cells activate brain-homing, autoreactive CD4(+) T cells in multiple sclerosis","volume":"175","author":"Jelcic","year":"2018","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.smim.2026.102016_bib54","doi-asserted-by":"crossref","first-page":"e1095","DOI":"10.1212\/WNL.0000000000201662","article-title":"Significance of myelin oligodendrocyte glycoprotein antibodies in CSF: a retrospective multicenter study","volume":"100","author":"Carta","year":"2023","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.smim.2026.102016_bib55","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/ana.26931","article-title":"Diagnostic utility of MOG antibody testing in cerebrospinal fluid","volume":"96","author":"Redenbaugh","year":"2024","journal-title":"Ann. Neurol."},{"issue":"6","key":"10.1016\/j.smim.2026.102016_bib56","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/ana.26226","article-title":"Complement activation is a prominent feature of MOGAD","volume":"90","author":"Keller","year":"2021","journal-title":"Ann. Neurol."},{"issue":"6","key":"10.1016\/j.smim.2026.102016_bib57","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1136\/jnnp-2023-332851","article-title":"The MOG antibody non-P42 epitope is predictive of a relapsing course in MOG antibody-associated disease","volume":"95","author":"Liyanage","year":"2024","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"2","key":"10.1016\/j.smim.2026.102016_bib58","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/ana.25291","article-title":"Pathogenicity of human antibodies against myelin oligodendrocyte glycoprotein","volume":"84","author":"Spadaro","year":"2018","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.smim.2026.102016_bib59","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.3389\/fimmu.2020.01188","article-title":"Comparative analysis of T-cell responses to aquaporin-4 and myelin oligodendrocyte glycoprotein in inflammatory demyelinating central nervous system diseases","volume":"11","author":"Hofer","year":"2020","journal-title":"Front Immunol."},{"issue":"6","key":"10.1016\/j.smim.2026.102016_bib60","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001075","article-title":"T-cell specificity influences disease heterogeneity in multiple sclerosis","volume":"8","author":"Cruciani","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"1","key":"10.1016\/j.smim.2026.102016_bib61","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-69182-w","article-title":"Identification of TNFAIP3 as relapse biomarker and potential therapeutic target for MOG antibody associated diseases","volume":"10","author":"Saxena","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.smim.2026.102016_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2023.578197","article-title":"NF-kappaB and STAT3 activation in CD4 T cells in pediatric MOG antibody-associated disease","volume":"384","author":"Corbali","year":"2023","journal-title":"J. Neuroimmunol."},{"issue":"7","key":"10.1016\/j.smim.2026.102016_bib63","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1002\/acn3.51378","article-title":"No strong HLA association with MOG antibody disease in the UK population","volume":"8","author":"Grant-Peters","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"2","key":"10.1016\/j.smim.2026.102016_bib64","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1056\/NEJMra1401483","article-title":"Multiple sclerosis","volume":"378","author":"Reich","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"5099","key":"10.1016\/j.smim.2026.102016_bib65","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1126\/science.7680493","article-title":"Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis","volume":"259","author":"Weiner","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.smim.2026.102016_bib66","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1749-6632.1996.tb21132.x","article-title":"Three-year open protocol continuation study of oral tolerization with myelin antigens in multiple sclerosis and design of a phase III pivotal trial","volume":"778","author":"Hohol","year":"1996","journal-title":"Ann. N. Y Acad. Sci."},{"issue":"8","key":"10.1016\/j.smim.2026.102016_bib67","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/j.1468-1331.2006.01533.x","article-title":"Intravenous synthetic peptide MBP8298 delayed disease progression in an HLA Class II-defined cohort of patients with progressive multiple sclerosis: results of a 24-month double-blind placebo-controlled clinical trial and 5 years of follow-up treatment","volume":"13","author":"Warren","year":"2006","journal-title":"Eur. J. Neurol."},{"issue":"1","key":"10.1016\/j.smim.2026.102016_bib68","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0022-510X(97)00130-5","article-title":"Tolerance induction to myelin basic protein by intravenous synthetic peptides containing epitope P85 VVHFFKNIVTP96 in chronic progressive multiple sclerosis","volume":"152","author":"Warren","year":"1997","journal-title":"J. Neurol. Sci."},{"issue":"1","key":"10.1016\/j.smim.2026.102016_bib69","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.cellimm.2012.11.004","article-title":"High dose antigen treatment with a peptide epitope of myelin basic protein modulates T cells in multiple sclerosis patients","volume":"280","author":"Loo","year":"2012","journal-title":"Cell. Immunol."},{"issue":"16","key":"10.1016\/j.smim.2026.102016_bib70","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1212\/WNL.0b013e318233b240","article-title":"A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS","volume":"77","author":"Freedman","year":"2011","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.smim.2026.102016_bib71","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000093","article-title":"Preclinical development and first-in-human study of ATX-MS-1467 for immunotherapy of MS","volume":"2","author":"Streeter","year":"2015","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"11","key":"10.1016\/j.smim.2026.102016_bib72","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000005118","article-title":"Effects of ATX-MS-1467 immunotherapy over 16 weeks in relapsing multiple sclerosis","volume":"90","author":"Chataway","year":"2018","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.smim.2026.102016_bib73","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1001\/jamaneurol.2013.3022","article-title":"Transdermal application of myelin peptides in multiple sclerosis treatment","volume":"70","author":"Walczak","year":"2013","journal-title":"Jama Neurol."},{"issue":"5","key":"10.1016\/j.smim.2026.102016_bib74","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/ana.22219","article-title":"Immune regulation of multiple sclerosis by transdermally applied myelin peptides","volume":"68","author":"Jurynczyk","year":"2010","journal-title":"Ann. Neurol."},{"issue":"12","key":"10.1016\/j.smim.2026.102016_bib75","first-page":"1412","article-title":"Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand (vol 6, pg 1167, 2000)","volume":"6","author":"Bielekova","year":"2000","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.smim.2026.102016_bib76","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/1531-8249(200011)48:5<758::AID-ANA9>3.0.CO;2-2","article-title":"NBI-5788, an altered MBP83-99 peptide, induces a T-helper 2-like immune response in multiple sclerosis patients","volume":"48","author":"Crowe","year":"2000","journal-title":"Ann. Neurol."},{"issue":"10","key":"10.1016\/j.smim.2026.102016_bib77","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1038\/80525","article-title":"Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group","volume":"6","author":"Kappos","year":"2000","journal-title":"Nat. Med."},{"issue":"10","key":"10.1016\/j.smim.2026.102016_bib78","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1001\/archneur.64.10.nct70002","article-title":"Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1\/2 trial","volume":"64","author":"Bar-Or","year":"2007","journal-title":"Arch. Neurol."},{"issue":"5","key":"10.1016\/j.smim.2026.102016_bib79","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/ana.21370","article-title":"Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis","volume":"63","author":"Garren","year":"2008","journal-title":"Ann. Neurol."},{"issue":"6","key":"10.1016\/j.smim.2026.102016_bib80","doi-asserted-by":"crossref","first-page":"3893","DOI":"10.4049\/jimmunol.172.6.3893","article-title":"Expansion and functional relevance of high-avidity myelin-specific CD4+ T cells in multiple sclerosis","volume":"172","author":"Bielekova","year":"2004","journal-title":"J. Immunol."},{"issue":"188","key":"10.1016\/j.smim.2026.102016_bib81","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006168","article-title":"Antigen-specific tolerance by autologous myelin peptide-coupled cells: a phase 1 trial in multiple sclerosis","volume":"5","author":"Lutterotti","year":"2013","journal-title":"Sci. Transl. Med."},{"issue":"5","key":"10.1016\/j.smim.2026.102016_bib82","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1177\/1352458514549405","article-title":"Antibody responses following induction of antigen-specific tolerance with antigen-coupled cells","volume":"21","author":"Peschl","year":"2015","journal-title":"Mult. Scler. J."},{"issue":"2","key":"10.1016\/j.smim.2026.102016_bib83","first-page":"890","article-title":"Establish Tolerance in MS with myelin-peptide coupled red blood cells \u2013 the Phase Ib ETIMSred trial","volume":"25","author":"Lutterotti","year":"2019","journal-title":"Mult. Scler. J."},{"issue":"17","key":"10.1016\/j.smim.2026.102016_bib84","doi-asserted-by":"crossref","first-page":"8463","DOI":"10.1073\/pnas.1820039116","article-title":"Immune tolerance in multiple sclerosis and neuromyelitis optica with peptide-loaded tolerogenic dendritic cells in a phase 1b trial","volume":"116","author":"Zubizarreta","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"8978","key":"10.1016\/j.smim.2026.102016_bib85","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0140-6736(95)91622-9","article-title":"Depletion of myelin-basic-protein autoreactive T cells by T-cell vaccination: pilot trial in multiple sclerosis","volume":"346","author":"Medaer","year":"1995","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.smim.2026.102016_bib86","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0090-1229(92)90108-Z","article-title":"T cell vaccination in multiple sclerosis: a preliminary report","volume":"62","author":"Hafler","year":"1992","journal-title":"Clin. Immunol. Immunopathol."},{"issue":"2","key":"10.1016\/j.smim.2026.102016_bib87","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S0165-5728(00)00235-6","article-title":"T cell vaccination in secondary progressive multiple sclerosis","volume":"107","author":"Correale","year":"2000","journal-title":"J. Neuroimmunol."},{"issue":"5127","key":"10.1016\/j.smim.2026.102016_bib88","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1126\/science.7690157","article-title":"MHC-restricted depletion of human myelin basic protein-reactive T cells by T cell vaccination","volume":"261","author":"Zhang","year":"1993","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.smim.2026.102016_bib89","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0165-5728(99)00157-5","article-title":"Myelin reactive T cells after T cell vaccination in multiple sclerosis: cytokine profile and depletion by additional immunizations","volume":"102","author":"Hermans","year":"2000","journal-title":"J. Neuroimmunol."},{"issue":"1","key":"10.1016\/j.smim.2026.102016_bib90","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1568-9972(03)00060-0","article-title":"T-cell vaccination in multiple sclerosis","volume":"3","author":"Achiron","year":"2004","journal-title":"Autoimmun. Rev."},{"issue":"2","key":"10.1016\/j.smim.2026.102016_bib91","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/PL00007867","article-title":"T cell vaccination in multiple sclerosis: results of a preliminary study","volume":"249","author":"Zhang","year":"2002","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.smim.2026.102016_bib92","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1046\/j.1365-2249.2003.02019.x","article-title":"T cell vaccination in multiple sclerosis patients with autologous CSF-derived activated T cells: results from a pilot study","volume":"131","author":"Van der Aa","year":"2003","journal-title":"Clin. Exp. Immunol."},{"issue":"2","key":"10.1016\/j.smim.2026.102016_bib93","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.clim.2009.01.005","article-title":"Autologous attenuated T-cell vaccine (Tovaxin) dose escalation in multiple sclerosis relapsing-remitting and secondary progressive patients nonresponsive to approved immunomodulatory therapies","volume":"131","author":"Loftus","year":"2009","journal-title":"Clin. Immunol."},{"issue":"12","key":"10.1016\/j.smim.2026.102016_bib94","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0050478","article-title":"T cell vaccination benefits relapsing progressive multiple sclerosis patients: a randomized, double-blind clinical trial","volume":"7","author":"Karussis","year":"2012","journal-title":"PLoS One"},{"issue":"6415","key":"10.1016\/j.smim.2026.102016_bib95","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/362068a0","article-title":"Selection for T-cell receptor V-Beta-D-Beta-J-Beta gene rearrangements with specificity for a myelin basic-protein peptide in brain-lesions of multiple-sclerosis","volume":"362","author":"Oksenberg","year":"1993","journal-title":"Nature"},{"issue":"20","key":"10.1016\/j.smim.2026.102016_bib96","doi-asserted-by":"crossref","first-page":"9161","DOI":"10.1073\/pnas.88.20.9161","article-title":"Preferential T-cell receptor beta-chain variable gene use in myelin basic protein-reactive T-cell clones from patients with multiple-sclerosis","volume":"88","author":"Kotzin","year":"1991","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"5","key":"10.1016\/j.smim.2026.102016_bib97","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1191\/1352458505ms1225oa","article-title":"A highly immunogenic trivalent T cell receptor peptide vaccine for multiple sclerosis","volume":"11","author":"Bourdette","year":"2005","journal-title":"Mult. Scler."},{"issue":"1","key":"10.1016\/j.smim.2026.102016_bib98","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1365-2567.2007.02703.x","article-title":"Therapeutic vaccination with a trivalent T-cell receptor (TCR) peptide vaccine restores deficient FoxP3 expression and TCR recognition in subjects with multiple sclerosis","volume":"123","author":"Vandenbark","year":"2008","journal-title":"Immunology"},{"issue":"11","key":"10.1016\/j.smim.2026.102016_bib99","doi-asserted-by":"crossref","first-page":"e955","DOI":"10.1212\/WNL.0000000000005118","article-title":"Effects of ATX-MS-1467 immunotherapy over 16 weeks in relapsing multiple sclerosis","volume":"90","author":"Chataway","year":"2018","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.smim.2026.102016_bib100","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/nri2858","article-title":"Antigen-presenting cell function in the tolerogenic liver environment","volume":"10","author":"Thomson","year":"2010","journal-title":"Nat. Rev. Immunol."},{"issue":"27","key":"10.1016\/j.smim.2026.102016_bib101","doi-asserted-by":"crossref","first-page":"9595","DOI":"10.1073\/pnas.0504131102","article-title":"Differential induction of IgE-mediated anaphylaxis after soluble vs. cell-bound tolerogenic peptide therapy of autoimmune encephalomyelitis","volume":"102","author":"Smith","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"8","key":"10.1016\/j.smim.2026.102016_bib102","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/RLU.0000000000005955","article-title":"Dampening of microglial activation with nasal foralumab administration in moderate Alzheimer's disease dementia","volume":"50","author":"Singhal","year":"2025","journal-title":"Clin. Nucl. Med"},{"key":"10.1016\/j.smim.2026.102016_bib103","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1146\/annurev.iy.12.040194.004113","article-title":"Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens","volume":"12","author":"Weiner","year":"1994","journal-title":"Annu Rev. Immunol."},{"issue":"9","key":"10.1016\/j.smim.2026.102016_bib104","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nri2153","article-title":"Antigen-specific tolerance strategies for the prevention and treatment of autoimmune disease","volume":"7","author":"Miller","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.smim.2026.102016_bib105","article-title":"Mechanistic and biomarker studies to demonstrate immune tolerance in multiple sclerosis","volume":"12","author":"Docampo","year":"2021","journal-title":"Front Immunol."},{"issue":"4","key":"10.1016\/j.smim.2026.102016_bib106","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2025.e00588","article-title":"Role of soluble biomarkers in treating multiple sclerosis and neuroinflammatory conditions","volume":"22","author":"Bose","year":"2025","journal-title":"Neurotherapeutics"},{"issue":"5","key":"10.1016\/j.smim.2026.102016_bib107","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41582-024-00955-x","article-title":"Neurofilaments as biomarkers in neurological disorders - towards clinical application","volume":"20","author":"Khalil","year":"2024","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.smim.2026.102016_bib108","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1002\/ana.410360719","article-title":"Serial contrast-enhanced magnetic resonance imaging in patients with early relapsing-remitting multiple sclerosis: implications for treatment trials","volume":"36","author":"Frank","year":"1994","journal-title":"Ann. Neurol."},{"issue":"23","key":"10.1016\/j.smim.2026.102016_bib109","doi-asserted-by":"crossref","first-page":"e3124","DOI":"10.1212\/WNL.0000000000010847","article-title":"Incidence of interattack asymptomatic brain lesions in NMO spectrum disorder","volume":"95","author":"Lee","year":"2020","journal-title":"Neurology"},{"issue":"18","key":"10.1016\/j.smim.2026.102016_bib110","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1212\/WNL.0000000000201263","article-title":"Frequency of new or enlarging lesions on MRI outside of clinical attacks in patients with MOG-antibody-associated disease","volume":"99","author":"Syc-Mazurek","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.smim.2026.102016_bib111","doi-asserted-by":"crossref","DOI":"10.1177\/17562864251357393","article-title":"Induction of immune tolerance in NMOSD and MOGAD","volume":"18","author":"Correale","year":"2025","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"7","key":"10.1016\/j.smim.2026.102016_bib112","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1212\/01.wnl.0000178984.30534.f9","article-title":"MRI as a marker for disease heterogeneity in multiple sclerosis","volume":"65","author":"Bielekova","year":"2005","journal-title":"Neurology"},{"issue":"188","key":"10.1016\/j.smim.2026.102016_bib113","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006168","article-title":"Antigen-specific tolerance by autologous myelin peptide-coupled cells: a phase 1 trial in multiple sclerosis","volume":"5","author":"Lutterotti","year":"2013","journal-title":"Sci. Transl. Med"},{"issue":"9","key":"10.1016\/j.smim.2026.102016_bib114","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1001\/jamaneurol.2013.3022","article-title":"Transdermal application of myelin peptides in multiple sclerosis treatment","volume":"70","author":"Walczak","year":"2013","journal-title":"JAMA Neurol."}],"container-title":["Seminars in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044532326000035?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044532326000035?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T03:25:32Z","timestamp":1777605932000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044532326000035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":114,"alternative-id":["S1044532326000035"],"URL":"https:\/\/doi.org\/10.1016\/j.smim.2026.102016","relation":{},"ISSN":["1044-5323"],"issn-type":[{"value":"1044-5323","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic immune tolerance for central nervous system autoimmune diseases \u2013 Prospects, challenges and pitfalls","name":"articletitle","label":"Article Title"},{"value":"Seminars in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.smim.2026.102016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102016"}}